Korro Bio: Funding, Investors & Team (Sep 2026)
Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms. Korro Bio was created to lead the field of RNA editing. The company is advancing a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. In 2018,
Korro Bio has raised $271M across 3 funding rounds on record, the most recent an undisclosed round of $85.0M announced in Mar 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Korro Bio Company Profile and Key Stats
Latest funding round on record: Mar 2026.
Korro Bio Funding Rounds
Korro Bio raised $116M in a Series B announced in Jan 2022.
2.3 years later, an undisclosed round of $70.0M was announced in Apr 2024.
1.9 years later, an undisclosed round of $85.0M was announced in Mar 2026.
Korro Bio Founders and Leadership Team
Contact details for the Korro Bio team: 2 of 2 have an email address on file.
Start 14-day free trial →Korro Bio Funding Compared to Other Biotechnology Startups
Korro Bio's latest round of $85.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Korro Bio in Biotechnology and Cambridge
Companies Similar to Korro Bio
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Korro Bio Funding FAQs
What does Korro Bio do?
Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms. Korro Bio was created to lead the field of RNA editing. The company is advancing a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. In 2018,
How much funding has Korro Bio raised?
Korro Bio has raised $271M across 3 rounds on record. The most recent is an undisclosed round of $85.0M announced in Mar 2026.
When did Korro Bio last raise funding?
Korro Bio's most recent funding round on record is an undisclosed round of $85.0M, announced in Mar 2026.
Who founded Korro Bio?
FundedIQ lists Andrew Fraley (Founder) at Korro Bio.
Who is the CEO of Korro Bio?
Ram Aiyar is listed as CEO at Korro Bio.
Where is Korro Bio headquartered?
Korro Bio is based in Cambridge, Massachusetts, United States.
How many employees does Korro Bio have?
Korro Bio is in the 51-100 employee band.
How does Korro Bio's funding compare to other Biotechnology startups?
Korro Bio's latest round of $85.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Korro Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Korro Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.